Zolbetuximab plus chemotherapy for locally advanced unresectable or metastatic stomach or gastroesophageal junction cancers: a plain language summary
This is a summary of two articles. The first article is about a clinical trial called SPOTLIGHT and it was published in the medical journal in in April of 2023. The second article is about a clinical trial called GLOW and it was published in the medical journal in July of 2023. Until recently, was t...
Gespeichert in:
| Veröffentlicht in: | Future oncology (London, England) England), 2024, Vol.20 (26), p.1861-1877 |
|---|---|
| Hauptverfasser: | , , , , , , , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 1877 |
|---|---|
| container_issue | 26 |
| container_start_page | 1861 |
| container_title | Future oncology (London, England) |
| container_volume | 20 |
| creator | Shitara, Kohei Shah, Manish A Lordick, Florian Bang, Yung-Jue Ilson, David Van Cutsem, Eric Enzinger, Peter Kim, Sunnie S Klempner, Samuel J Moran, Diarmuid Park, Jung Wook Bhattacharya, Pranob Ajani, Jaffer A Xu, Rui-Hua |
| description | This is a summary of two articles. The first article is about a clinical trial called SPOTLIGHT and it was published in the medical journal
in in April of 2023. The second article is about a clinical trial called GLOW and it was published in the medical journal
in July of 2023.
Until recently,
was the first treatment given to people with stomach cancer or
(or
) cancer that is
or
. When cancer cells have high amounts of the
but do not have high amounts of the protein
, the cancer is known as CLDN18.2-positive (or CLDN18.2+) and HER2-negative (or HER2-). New medicines to treat cancer are being developed. These medicines attach to proteins on cancer cells to help the body recognize and kill cancer cells.The clinical trials SPOTLIGHT and GLOW included participants with CLDN18.2+ and HER2- stomach or GEJ cancer that was locally advanced unresectable or metastatic. These trials looked at whether adding a medicine called zolbetuximab to chemotherapy as the first treatment for cancer helped people live longer before their tumors grew bigger or new tumors grew, after starting the trial. These studies also looked at whether adding zolbetuximab to chemotherapy helped people live longer after starting the trial.
In SPOTLIGHT and GLOW, on average, participants assigned to zolbetuximab plus chemotherapy lived 1.4 to 1.9 months longer before their tumors grew bigger or new tumors grew, after starting the trial, than participants assigned to a
plus chemotherapy. On average, participants assigned to zolbetuximab plus chemotherapy also lived 2.2 to 2.7 months longer, after starting the trial, than participants assigned to a placebo plus chemotherapy. These results suggest that zolbetuximab plus chemotherapy could be a new first treatment for people with CLDN18.2+ and HER2- stomach or GEJ cancer that is locally advanced unresectable or metastatic.
NCT03504397 (SPOTLIGHT); NCT03653507 (GLOW). |
| doi_str_mv | 10.1080/14796694.2024.2342107 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_11500822</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>3066788676</sourcerecordid><originalsourceid>FETCH-LOGICAL-c2757-107882de30ff8777fca1b65249ddd8ca3e33ea238986e2d9d0addb89475a3d5f3</originalsourceid><addsrcrecordid>eNpVkctu1TAQhiMEoqXwCCAv2aT4ksQOG4QqblIlNrBhY03syUkqJw6-VD0PwvviqKcVbGxr_M0__-ivqteMXjKq6DvWyL7r-uaSU14O0XBG5ZPqnMmmqZWg7Gl5F6beobPqRYw3lDZStPR5dSaU6hjvm_Pqzy_vBkz5bl5gIJvLkZgJF58mDLAdyegDcd6Ac0cC9hZWg5bkNWBEk2BwSAqwYIKYIM2GxOQXMNNePZRa8Bj9NsEBwZGbvJo0-5WYXSbE9wTKRJhX4mA95AKRmJcFwvFl9WwEF_HV6b6ofn7-9OPqa339_cu3q4_XteGylXXZWCluUdBxVFLK0QAbupY3vbVWGRAoBAIXqlcdcttbCtYOqm9kC8K2o7ioPtzrbnlY0BpcUwCntzDvLrSHWf__s86TPvhbzVhLqeK8KLw9KQT_O2NMepmjQVc2Qp-jFrTrislOdgVt71ETfIwBx8c5jOo9U_2Qqd4z1adMS9-bf00-dj2EKP4CU5iiiw</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>3066788676</pqid></control><display><type>article</type><title>Zolbetuximab plus chemotherapy for locally advanced unresectable or metastatic stomach or gastroesophageal junction cancers: a plain language summary</title><source>MEDLINE</source><source>PubMed Central</source><creator>Shitara, Kohei ; Shah, Manish A ; Lordick, Florian ; Bang, Yung-Jue ; Ilson, David ; Van Cutsem, Eric ; Enzinger, Peter ; Kim, Sunnie S ; Klempner, Samuel J ; Moran, Diarmuid ; Park, Jung Wook ; Bhattacharya, Pranob ; Ajani, Jaffer A ; Xu, Rui-Hua</creator><creatorcontrib>Shitara, Kohei ; Shah, Manish A ; Lordick, Florian ; Bang, Yung-Jue ; Ilson, David ; Van Cutsem, Eric ; Enzinger, Peter ; Kim, Sunnie S ; Klempner, Samuel J ; Moran, Diarmuid ; Park, Jung Wook ; Bhattacharya, Pranob ; Ajani, Jaffer A ; Xu, Rui-Hua</creatorcontrib><description>This is a summary of two articles. The first article is about a clinical trial called SPOTLIGHT and it was published in the medical journal
in in April of 2023. The second article is about a clinical trial called GLOW and it was published in the medical journal
in July of 2023.
Until recently,
was the first treatment given to people with stomach cancer or
(or
) cancer that is
or
. When cancer cells have high amounts of the
but do not have high amounts of the protein
, the cancer is known as CLDN18.2-positive (or CLDN18.2+) and HER2-negative (or HER2-). New medicines to treat cancer are being developed. These medicines attach to proteins on cancer cells to help the body recognize and kill cancer cells.The clinical trials SPOTLIGHT and GLOW included participants with CLDN18.2+ and HER2- stomach or GEJ cancer that was locally advanced unresectable or metastatic. These trials looked at whether adding a medicine called zolbetuximab to chemotherapy as the first treatment for cancer helped people live longer before their tumors grew bigger or new tumors grew, after starting the trial. These studies also looked at whether adding zolbetuximab to chemotherapy helped people live longer after starting the trial.
In SPOTLIGHT and GLOW, on average, participants assigned to zolbetuximab plus chemotherapy lived 1.4 to 1.9 months longer before their tumors grew bigger or new tumors grew, after starting the trial, than participants assigned to a
plus chemotherapy. On average, participants assigned to zolbetuximab plus chemotherapy also lived 2.2 to 2.7 months longer, after starting the trial, than participants assigned to a placebo plus chemotherapy. These results suggest that zolbetuximab plus chemotherapy could be a new first treatment for people with CLDN18.2+ and HER2- stomach or GEJ cancer that is locally advanced unresectable or metastatic.
NCT03504397 (SPOTLIGHT); NCT03653507 (GLOW).</description><identifier>ISSN: 1479-6694</identifier><identifier>ISSN: 1744-8301</identifier><identifier>EISSN: 1744-8301</identifier><identifier>DOI: 10.1080/14796694.2024.2342107</identifier><identifier>PMID: 38861294</identifier><language>eng</language><publisher>England: Taylor & Francis</publisher><subject>Antineoplastic Combined Chemotherapy Protocols - adverse effects ; Antineoplastic Combined Chemotherapy Protocols - therapeutic use ; Claudins - metabolism ; Clinical Trials, Phase III as Topic ; Esophageal Neoplasms - drug therapy ; Esophageal Neoplasms - pathology ; Esophagogastric Junction - pathology ; Humans ; Neoplasm Metastasis ; Plain Language Summary ; Plain Language Summary of Publication ; Randomized Controlled Trials as Topic ; Receptor, ErbB-2 - metabolism ; Stomach Neoplasms - drug therapy ; Stomach Neoplasms - pathology</subject><ispartof>Future oncology (London, England), 2024, Vol.20 (26), p.1861-1877</ispartof><rights>2024 The Author(s). Published by Informa UK Limited, trading as Taylor & Francis Group 2024</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC11500822/pdf/$$EPDF$$P50$$Gpubmedcentral$$Hfree_for_read</linktopdf><linktohtml>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC11500822/$$EHTML$$P50$$Gpubmedcentral$$Hfree_for_read</linktohtml><link.rule.ids>230,314,723,776,780,881,4010,27900,27901,27902,53766,53768</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/38861294$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Shitara, Kohei</creatorcontrib><creatorcontrib>Shah, Manish A</creatorcontrib><creatorcontrib>Lordick, Florian</creatorcontrib><creatorcontrib>Bang, Yung-Jue</creatorcontrib><creatorcontrib>Ilson, David</creatorcontrib><creatorcontrib>Van Cutsem, Eric</creatorcontrib><creatorcontrib>Enzinger, Peter</creatorcontrib><creatorcontrib>Kim, Sunnie S</creatorcontrib><creatorcontrib>Klempner, Samuel J</creatorcontrib><creatorcontrib>Moran, Diarmuid</creatorcontrib><creatorcontrib>Park, Jung Wook</creatorcontrib><creatorcontrib>Bhattacharya, Pranob</creatorcontrib><creatorcontrib>Ajani, Jaffer A</creatorcontrib><creatorcontrib>Xu, Rui-Hua</creatorcontrib><title>Zolbetuximab plus chemotherapy for locally advanced unresectable or metastatic stomach or gastroesophageal junction cancers: a plain language summary</title><title>Future oncology (London, England)</title><addtitle>Future Oncol</addtitle><description>This is a summary of two articles. The first article is about a clinical trial called SPOTLIGHT and it was published in the medical journal
in in April of 2023. The second article is about a clinical trial called GLOW and it was published in the medical journal
in July of 2023.
Until recently,
was the first treatment given to people with stomach cancer or
(or
) cancer that is
or
. When cancer cells have high amounts of the
but do not have high amounts of the protein
, the cancer is known as CLDN18.2-positive (or CLDN18.2+) and HER2-negative (or HER2-). New medicines to treat cancer are being developed. These medicines attach to proteins on cancer cells to help the body recognize and kill cancer cells.The clinical trials SPOTLIGHT and GLOW included participants with CLDN18.2+ and HER2- stomach or GEJ cancer that was locally advanced unresectable or metastatic. These trials looked at whether adding a medicine called zolbetuximab to chemotherapy as the first treatment for cancer helped people live longer before their tumors grew bigger or new tumors grew, after starting the trial. These studies also looked at whether adding zolbetuximab to chemotherapy helped people live longer after starting the trial.
In SPOTLIGHT and GLOW, on average, participants assigned to zolbetuximab plus chemotherapy lived 1.4 to 1.9 months longer before their tumors grew bigger or new tumors grew, after starting the trial, than participants assigned to a
plus chemotherapy. On average, participants assigned to zolbetuximab plus chemotherapy also lived 2.2 to 2.7 months longer, after starting the trial, than participants assigned to a placebo plus chemotherapy. These results suggest that zolbetuximab plus chemotherapy could be a new first treatment for people with CLDN18.2+ and HER2- stomach or GEJ cancer that is locally advanced unresectable or metastatic.
NCT03504397 (SPOTLIGHT); NCT03653507 (GLOW).</description><subject>Antineoplastic Combined Chemotherapy Protocols - adverse effects</subject><subject>Antineoplastic Combined Chemotherapy Protocols - therapeutic use</subject><subject>Claudins - metabolism</subject><subject>Clinical Trials, Phase III as Topic</subject><subject>Esophageal Neoplasms - drug therapy</subject><subject>Esophageal Neoplasms - pathology</subject><subject>Esophagogastric Junction - pathology</subject><subject>Humans</subject><subject>Neoplasm Metastasis</subject><subject>Plain Language Summary</subject><subject>Plain Language Summary of Publication</subject><subject>Randomized Controlled Trials as Topic</subject><subject>Receptor, ErbB-2 - metabolism</subject><subject>Stomach Neoplasms - drug therapy</subject><subject>Stomach Neoplasms - pathology</subject><issn>1479-6694</issn><issn>1744-8301</issn><issn>1744-8301</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2024</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNpVkctu1TAQhiMEoqXwCCAv2aT4ksQOG4QqblIlNrBhY03syUkqJw6-VD0PwvviqKcVbGxr_M0__-ivqteMXjKq6DvWyL7r-uaSU14O0XBG5ZPqnMmmqZWg7Gl5F6beobPqRYw3lDZStPR5dSaU6hjvm_Pqzy_vBkz5bl5gIJvLkZgJF58mDLAdyegDcd6Ac0cC9hZWg5bkNWBEk2BwSAqwYIKYIM2GxOQXMNNePZRa8Bj9NsEBwZGbvJo0-5WYXSbE9wTKRJhX4mA95AKRmJcFwvFl9WwEF_HV6b6ofn7-9OPqa339_cu3q4_XteGylXXZWCluUdBxVFLK0QAbupY3vbVWGRAoBAIXqlcdcttbCtYOqm9kC8K2o7ioPtzrbnlY0BpcUwCntzDvLrSHWf__s86TPvhbzVhLqeK8KLw9KQT_O2NMepmjQVc2Qp-jFrTrislOdgVt71ETfIwBx8c5jOo9U_2Qqd4z1adMS9-bf00-dj2EKP4CU5iiiw</recordid><startdate>2024</startdate><enddate>2024</enddate><creator>Shitara, Kohei</creator><creator>Shah, Manish A</creator><creator>Lordick, Florian</creator><creator>Bang, Yung-Jue</creator><creator>Ilson, David</creator><creator>Van Cutsem, Eric</creator><creator>Enzinger, Peter</creator><creator>Kim, Sunnie S</creator><creator>Klempner, Samuel J</creator><creator>Moran, Diarmuid</creator><creator>Park, Jung Wook</creator><creator>Bhattacharya, Pranob</creator><creator>Ajani, Jaffer A</creator><creator>Xu, Rui-Hua</creator><general>Taylor & Francis</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope><scope>5PM</scope></search><sort><creationdate>2024</creationdate><title>Zolbetuximab plus chemotherapy for locally advanced unresectable or metastatic stomach or gastroesophageal junction cancers: a plain language summary</title><author>Shitara, Kohei ; Shah, Manish A ; Lordick, Florian ; Bang, Yung-Jue ; Ilson, David ; Van Cutsem, Eric ; Enzinger, Peter ; Kim, Sunnie S ; Klempner, Samuel J ; Moran, Diarmuid ; Park, Jung Wook ; Bhattacharya, Pranob ; Ajani, Jaffer A ; Xu, Rui-Hua</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c2757-107882de30ff8777fca1b65249ddd8ca3e33ea238986e2d9d0addb89475a3d5f3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2024</creationdate><topic>Antineoplastic Combined Chemotherapy Protocols - adverse effects</topic><topic>Antineoplastic Combined Chemotherapy Protocols - therapeutic use</topic><topic>Claudins - metabolism</topic><topic>Clinical Trials, Phase III as Topic</topic><topic>Esophageal Neoplasms - drug therapy</topic><topic>Esophageal Neoplasms - pathology</topic><topic>Esophagogastric Junction - pathology</topic><topic>Humans</topic><topic>Neoplasm Metastasis</topic><topic>Plain Language Summary</topic><topic>Plain Language Summary of Publication</topic><topic>Randomized Controlled Trials as Topic</topic><topic>Receptor, ErbB-2 - metabolism</topic><topic>Stomach Neoplasms - drug therapy</topic><topic>Stomach Neoplasms - pathology</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Shitara, Kohei</creatorcontrib><creatorcontrib>Shah, Manish A</creatorcontrib><creatorcontrib>Lordick, Florian</creatorcontrib><creatorcontrib>Bang, Yung-Jue</creatorcontrib><creatorcontrib>Ilson, David</creatorcontrib><creatorcontrib>Van Cutsem, Eric</creatorcontrib><creatorcontrib>Enzinger, Peter</creatorcontrib><creatorcontrib>Kim, Sunnie S</creatorcontrib><creatorcontrib>Klempner, Samuel J</creatorcontrib><creatorcontrib>Moran, Diarmuid</creatorcontrib><creatorcontrib>Park, Jung Wook</creatorcontrib><creatorcontrib>Bhattacharya, Pranob</creatorcontrib><creatorcontrib>Ajani, Jaffer A</creatorcontrib><creatorcontrib>Xu, Rui-Hua</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>Future oncology (London, England)</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Shitara, Kohei</au><au>Shah, Manish A</au><au>Lordick, Florian</au><au>Bang, Yung-Jue</au><au>Ilson, David</au><au>Van Cutsem, Eric</au><au>Enzinger, Peter</au><au>Kim, Sunnie S</au><au>Klempner, Samuel J</au><au>Moran, Diarmuid</au><au>Park, Jung Wook</au><au>Bhattacharya, Pranob</au><au>Ajani, Jaffer A</au><au>Xu, Rui-Hua</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Zolbetuximab plus chemotherapy for locally advanced unresectable or metastatic stomach or gastroesophageal junction cancers: a plain language summary</atitle><jtitle>Future oncology (London, England)</jtitle><addtitle>Future Oncol</addtitle><date>2024</date><risdate>2024</risdate><volume>20</volume><issue>26</issue><spage>1861</spage><epage>1877</epage><pages>1861-1877</pages><issn>1479-6694</issn><issn>1744-8301</issn><eissn>1744-8301</eissn><abstract>This is a summary of two articles. The first article is about a clinical trial called SPOTLIGHT and it was published in the medical journal
in in April of 2023. The second article is about a clinical trial called GLOW and it was published in the medical journal
in July of 2023.
Until recently,
was the first treatment given to people with stomach cancer or
(or
) cancer that is
or
. When cancer cells have high amounts of the
but do not have high amounts of the protein
, the cancer is known as CLDN18.2-positive (or CLDN18.2+) and HER2-negative (or HER2-). New medicines to treat cancer are being developed. These medicines attach to proteins on cancer cells to help the body recognize and kill cancer cells.The clinical trials SPOTLIGHT and GLOW included participants with CLDN18.2+ and HER2- stomach or GEJ cancer that was locally advanced unresectable or metastatic. These trials looked at whether adding a medicine called zolbetuximab to chemotherapy as the first treatment for cancer helped people live longer before their tumors grew bigger or new tumors grew, after starting the trial. These studies also looked at whether adding zolbetuximab to chemotherapy helped people live longer after starting the trial.
In SPOTLIGHT and GLOW, on average, participants assigned to zolbetuximab plus chemotherapy lived 1.4 to 1.9 months longer before their tumors grew bigger or new tumors grew, after starting the trial, than participants assigned to a
plus chemotherapy. On average, participants assigned to zolbetuximab plus chemotherapy also lived 2.2 to 2.7 months longer, after starting the trial, than participants assigned to a placebo plus chemotherapy. These results suggest that zolbetuximab plus chemotherapy could be a new first treatment for people with CLDN18.2+ and HER2- stomach or GEJ cancer that is locally advanced unresectable or metastatic.
NCT03504397 (SPOTLIGHT); NCT03653507 (GLOW).</abstract><cop>England</cop><pub>Taylor & Francis</pub><pmid>38861294</pmid><doi>10.1080/14796694.2024.2342107</doi><tpages>17</tpages><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 1479-6694 |
| ispartof | Future oncology (London, England), 2024, Vol.20 (26), p.1861-1877 |
| issn | 1479-6694 1744-8301 1744-8301 |
| language | eng |
| recordid | cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_11500822 |
| source | MEDLINE; PubMed Central |
| subjects | Antineoplastic Combined Chemotherapy Protocols - adverse effects Antineoplastic Combined Chemotherapy Protocols - therapeutic use Claudins - metabolism Clinical Trials, Phase III as Topic Esophageal Neoplasms - drug therapy Esophageal Neoplasms - pathology Esophagogastric Junction - pathology Humans Neoplasm Metastasis Plain Language Summary Plain Language Summary of Publication Randomized Controlled Trials as Topic Receptor, ErbB-2 - metabolism Stomach Neoplasms - drug therapy Stomach Neoplasms - pathology |
| title | Zolbetuximab plus chemotherapy for locally advanced unresectable or metastatic stomach or gastroesophageal junction cancers: a plain language summary |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-21T19%3A54%3A09IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Zolbetuximab%20plus%20chemotherapy%20for%20locally%20advanced%20unresectable%20or%20metastatic%20stomach%20or%20gastroesophageal%20junction%20cancers:%20a%20plain%20language%20summary&rft.jtitle=Future%20oncology%20(London,%20England)&rft.au=Shitara,%20Kohei&rft.date=2024&rft.volume=20&rft.issue=26&rft.spage=1861&rft.epage=1877&rft.pages=1861-1877&rft.issn=1479-6694&rft.eissn=1744-8301&rft_id=info:doi/10.1080/14796694.2024.2342107&rft_dat=%3Cproquest_pubme%3E3066788676%3C/proquest_pubme%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=3066788676&rft_id=info:pmid/38861294&rfr_iscdi=true |